Medicinal Cannabis and Wasting Syndrome: What Can It Do? Cachexia is a condition, also known as ‘wasting syndrome’, characterised by loss of body mass associated
Medical Cannabis Research
Australia’s leading contract research organization focused exclusively on medicinal cannabis treatments
About Applied Cannabis Research
Accelerate your medicinal cannabis clinical development program. From project management through to clinical trial monitoring, management and patient recruitment, we’re Australia’s leading contract research organization in the medicinal cannabis sector.
Medicinal Cannabis Research needs a different approach. Intellectual property positions are different. Budgets are smaller. Timescales are shorter. Regulatory pathways are newly established and more complex. Product companies undertaking research in the Medicinal Cannabis sector need a different research partner. A partner with hands-on experience in the sector; direct access to the largest patient pool in the country; multiple treatment sites in every state; data collection platforms that are compliant, and tailored to the medicinal cannabis sector.
Applied Cannabis Research is dedicated to assisting medicinal cannabis companies with the development of their products with a single, unified vision: the faster the clinical development stage is accomplished the quicker medicinal cannabis treatments reach those who need them – the patients.
Why Australia for Cannabis Research?
Dr John Barlow is the Principal Investigator for the CACOS Study, Australia’s largest medicinal cannabis observational trial. He has more than 10 years experience in clinical trials in a range of medical, surgical and public health fields, particularly oncology, neurology and orthopaedics. John is a former Associate Professor in the Department of Medicine at Monash University and was a Neil Hamilton Fairley Fellow of the National Health and Medical Research Council. He holds a PhD from Monash University and has published more than 200 peer reviewed papers and abstracts encompassing a range of topics including endocrinology, clinical chemistry and drug evaluation.
Advisory board member
Dr Melissa Benson sits on the Applied Cannabis Research advisory board. She brings her experience and expertise in conducting clinical trials with medicinal cannabis products to the broader ACR team in an advisory capacity. Melissa holds a PhD in Neuropharmacology from the University of Queensland and has completed postdoctoral fellowships focused on drug development in the fields of refractory epilepsy and cannabinoids. She has also completed postgraduate studies in intellectual property commercialisation. Melissa has managed sites for registration level pharmaceutical clinical trials (outside of cannabis) and was previously Clinical team leader at the Lambert Initiative for Cannabinoid Therapeutics based at the University of Sydney, where she oversaw development, start-up, and execution of clinical trials with medicinal cannabinoids.
ACR receives funding from industry clients including but not limited to licensed medicinal cannabis producers and suppliers.
The GreenFund – A new study has found that medicinal cannabis may be able to reduce the intensity of chronic pain in patients by as
STOCKHEAD MGC (ASX:MXC) will conduct a head-to-head clinical study on severe intractable epilepsy in collaboration with Cannabis Access Clinics and Epilepsy Action Australia, a direct comparison